MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance

About 76% of patients with lung adenocarcinoma harbor activating mutations in the receptor tyrosine kinase (RTK)/RAS/RAF pathways, leading to aberrant activation of the mitogen‐activated protein kinase (MAPK) pathways particularly the MAPK/ERK pathway. However, many lung adenocarcinomas lacking thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xuan, Chen, Guangming, Gao, Chenxi, Zhang, Dennis Han, Kuan, Shih‐Fan, Stabile, Laura P., Liu, Guoxiang, Hu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467491/
https://www.ncbi.nlm.nih.gov/pubmed/28306189
http://dx.doi.org/10.1002/1878-0261.12055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467491/
https://www.ncbi.nlm.nih.gov/pubmed/28306189
http://dx.doi.org/10.1002/1878-0261.12055

Ejemplares similares